Clinical trials: Cabozantinib
Renal Cell Carcinoma (RCC)
First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain
This retrospective observational study will use anonymized electronic medical records from the BIG-PAC® database to describe outcomes and treatment management for adults in Spain with advanced or metastatic renal cell carcinoma…
- Trial name
- INSPIRE-RCC (NCT07852884)
- Testing
- First-line systemic regimens
- Where
- Spain
- Volunteers
- 1,200 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Non-small Cell Lung Cancer
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy
- Trial name
- CheckMate 79X (NCT04151563)
- Testing
- nivolumab, ipilimumab, cabozantinib
- Where
- 23 sites in United States, Argentina and 8 more
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC.
- Conditions
- Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer
- Trial name
- NCT03634540
- Testing
- Belzutifan, Cabozantinib
- Where
- 10 sites in United States
- Volunteers
- 118 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-2 (NCT01522443)
- Testing
- cabozantinib, mitoxantrone, prednisone
- Where
- 82 sites in United States, Australia and 3 more
- Volunteers
- 119 people
- Sponsor
- Exelixis
Clear Cell Renal Cell Carcinoma (ccRCC)
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)
- Trial name
- NCT07848295
- Testing
- BMS-986527, Nivolumab, Cabozantinib
- Where
- 17 sites in United States, Belgium and 5 more
- Volunteers
- 112 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Prostate Cancer, Castration Resistant Prostate Cancer
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
- Trial name
- NCT01995058
- Testing
- cabozantinib, abiraterone, prednisone
- Where
- 20 sites in United States
- Volunteers
- 54 people
- Sponsor
- Exelixis
Cancer
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during…
- Trial name
- IMbrella B (NCT03768063)
- Testing
- Atezolizumab, Bevacizumab, Alectinib
- Where
- 80 sites in United States, Australia and 22 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous…
- Trial name
- COSMIC-312 (NCT03755791)
- Testing
- Cabozantinib, Sorafenib, Atezolizumab
- Where
- 245 sites in United States, Argentina and 32 more
- Volunteers
- 837 people
- Sponsor
- Exelixis
Healthy, Renal Impairment
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
The main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of cabozantinib in adult subjects with impaired renal function compared with healthy adult subjects.
- Trial name
- NCT01761773
- Testing
- cabozantinib
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Exelixis
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
- Trial name
- NCT04586231
- Testing
- Belzutifan, Lenvatinib, Cabozantinib
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 747 people
- Sponsor
- Merck Sharp & Dohme LLC
Von Hippel-Lindau Disease, Malignant Neoplasms
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery Solid…
- Trial name
- NCT07405164
- Testing
- Belzutifan, Nivolumab, Lenvatinib
- Where
- 57 sites in United States, Australia and 20 more
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the…
- Trial name
- NCT07011719
- Testing
- Casdatifan, Cabozantinib
- Where
- 183 sites in United States, Argentina and 15 more
- Volunteers
- 720 people
- Sponsor
- Arcus Biosciences, Inc.
Neuroendocrine Tumors
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs). These tumors can appear in all parts of the body.
- Trial name
- CaboLife (NCT07314164)
- Where
- 41 sites in Austria, Germany
- Volunteers
- 150 people
- Sponsor
- Ipsen
Lymphoma, Cancer
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
- Conditions
- Lymphoma, Cancer, Thyroid Carcinoma
- Trial name
- NCT00215605
- Testing
- XL184
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Exelixis
Glioblastoma, Giant Cell Glioblastoma
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
The purpose of this study is to determine the highest safe dose of XL184 administered orally in combination with temozolomide (TMZ, Temodar®) and radiation therapy (RT).
- Conditions
- Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- NCT00960492
- Testing
- XL184, temozolomide, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Exelixis
Carcinoma, Renal Cell
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally…
- Trial name
- CONTACT-03 (NCT04338269)
- Testing
- Atezolizumab, Cabozantinib
- Where
- 135 sites in United States, Argentina and 13 more
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
- Trial name
- CheckMate 9ER (NCT03141177)
- Testing
- Nivolumab, Cabozantinib, Sunitinib
- Where
- 135 sites in United States, Argentina and 16 more
- Volunteers
- 701 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment…
- Trial name
- LITESPARK-033 (NCT07227402)
- Testing
- Belzutifan, Zanzalintinib, Cabozantinib
- Where
- 127 sites in United States, Argentina and 21 more
- Volunteers
- 904 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Renal Cell Carcinoma (aRCC)
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination…
- Trial name
- CARINA (NCT04957160)
- Where
- 9 sites in United Kingdom
- Volunteers
- 281 people
- Sponsor
- Ipsen
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men…
- Trial name
- CONTACT-02 (NCT04446117)
- Testing
- Cabozantinib, Atezolizumab, Abiraterone Acetate
- Where
- 280 sites in United States, Argentina and 25 more
- Volunteers
- 575 people
- Sponsor
- Exelixis